We are live on ! Find out more
LXEO icon

Lexeo Therapeutics

31 hedge funds and large institutions have $217M invested in Lexeo Therapeutics in 2023 Q4 according to their latest regulatory filings, with 31 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

60.73% more ownership

Funds ownership: 0%60.73% (+61%)

Holders
31
Holders Change
+31
Holders Change %
% of All Funds
0.45%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.03%
New
31
Increased
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Bank of America
26
Bank of America
North Carolina
$109K +$101K +8,128 New
TRCT
27
Tower Research Capital (TRC)
New York
$20K +$18.5K +1,490 New
Qube Research & Technologies (QRT)
28
Qube Research & Technologies (QRT)
United Kingdom
$8.09K +$7.49K +603 New
SPIA
29
Steward Partners Investment Advisory
New York
$4.33K +$4.01K +323 New
JP Morgan Chase
30
JP Morgan Chase
New York
$1.5K +$1.39K +112 New
Wells Fargo
31
Wells Fargo
California
$966 +$894 +72 New

LXEO Hedge Fund Activity: Q4 2023 in Review

31 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Lexeo Therapeutics (LXEO) for Q4 2023, worth a combined $217M.

Buyers outnumbered sellers: 31 funds opened new LXEO positions and 0 closed out — a net gain of 31 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Eventide Asset Management, opening a new position worth an estimated $37.3M.

  • 31 institutional investors held Lexeo Therapeutics (LXEO) as of Q4 2023, up from 0 in Q3 2023.
  • Funds reported $217M of Lexeo Therapeutics stock for Q4 2023.
  • 31 funds opened new Lexeo Therapeutics positions in Q4 2023 and 0 closed out, a net change of +31 holders.
  • The largest Lexeo Therapeutics buyer in Q4 2023 was Eventide Asset Management, an estimated $37.3M added.

Based on aggregated 13F filings for Q4 2023.